OBSEF (ObsEva) Total Liabilities: $8.06 Mil (As of Dec. 2022)


OBSEF ObsEva SA OBSEF
18 GF Score
Price $0.00
View Full Analysis

What is ObsEva Total Liabilities?

ObsEva OBSEF -99.00% 18 Total Liabilities is $8.06 Mil as of Dec. 2022. GuruFocus rates OBSEF with a GF Score™ of 18/100.

ObsEva's Total Liabilities for the quarter that ended in Dec. 2022 was $8.06 Mil.

ObsEva's quarterly Total Liabilities declined from Jun. 2022 ($56.29 Mil) to Sep. 2022 ($19.96 Mil) and declined from Sep. 2022 ($19.96 Mil) to Dec. 2022 ($8.06 Mil).

ObsEva's annual Total Liabilities declined from Dec. 2020 ($57.09 Mil) to Dec. 2021 ($51.63 Mil) and declined from Dec. 2021 ($51.63 Mil) to Dec. 2022 ($8.06 Mil).

ObsEva Total Liabilities Historical Data

* Premium members only.

The historical data trend for ObsEva's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ObsEva Total Liabilities Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 20.52 54.99 57.09 51.63 8.06

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.63 61.18 56.29 19.96 8.06
OBSEF
18GF Score
ObsEva SA OBSEF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ObsEva Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ObsEva's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.186+(0+0.293
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.582+0)
=8.06

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=16.544-8.483
=8.06

ObsEva's Total Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.186+(0+0.293
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.582+0)
=8.06

Total Liabilities=Total Assets (Q: Dec. 2022 )-Total Equity (Q: Dec. 2022 )
=16.544-8.483
=8.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $8.06 Mil mean?
ObsEva (OBSEF) has a Total Liabilities of $8.06 Mil as of Dec. 2022. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ObsEva and its competitors.
Is ObsEva's Total Liabilities too high?
ObsEva's current Total Liabilities is $8.06 Mil. Overall, ObsEva has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does ObsEva's Total Liabilities compare to VRTX and REGN?
ObsEva's Total Liabilities of $8.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ObsEva and its competitors. ObsEva's current Total Liabilities is $8.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ObsEva stock overvalued right now?
ObsEva (OBSEF) has a current Total Liabilities of $8.06 Mil. The current Total Liabilities is $8.06 Mil. ObsEva's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ObsEva (OBSEF), the current Total Liabilities is $8.06 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ObsEva Business Description

Address Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
18GF Score

Get the complete analysis for OBSEF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price